A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery

PHASE3TerminatedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

March 31, 2004

Conditions
Pain
Interventions
DRUG

Parecoxib/Valdecoxib

A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3

DRUG

Placebo

A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3

Trial Locations (8)

2031

Pfizer Investigational Site, Randwick

2145

Pfizer Investigational Site, Westmead

3084

Pfizer Investigational Site, Heidelberg

3181

Pfizer Investigational Site, Prahran

4108

Pfizer Investigational Site, Coopers Plain

4814

Pfizer Investigational Site, Townsville

6847

Pfizer Investigational Site, Perth

Unknown

Pfizer Investigational Site, Port Macquarie

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY